Overview of Vitiligo Research July - September 2013

This is a VR Foundation’s regular review of research results in the vitiligo field which were indexed in the PubMed database (www.ncbi.nlm.nih.gov/pubmed) for the period from July 2013 till September 2013. Abstracts of papers were retrieved from the PubMed database using the search term “vitiligo” with a filter set up to retrieve records with creation date between July 01, 2013 and September 30, 2013. Retrieved records were manually checked for a relevance to and significance for the field of vitiligo research. Forty seven records have been selected for inclusion into this quarterly overview.

Highlights

  • Broad-band UVA phototherapy reported to be superior over narrow-band UVB treatment
  • Foam formulation of clobetasol propionate may provide additional benefits in vitiligo treatment
  • Additional evidence of regulatory T-cell role in vitiligo provided
  • Sunscreen cream with bandpass centered at 311 nm has been described as a novel anti-vitiligo weapon
  • Lesional keratinocytes might be deficient in NB-UVB response thus contributing to failure of phototherapy in repigmentation
  • Every eighth patients treated with oral mini-pulse dexamethasone therapy to stop vitiligo progression will relapse at average of about 2.5 years after successful treatment
  • Rituximab, anti-CD20 recombinant monoclonal antibody, may be efficient in vitiligo treatment

Full report is available for download in pdf

image description

I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.

All

Famous vitiligans

FAQ

All FAQs

To download this free file, please tell us a little bit about yourself.

Close